{"title":"An evaluation of known predictive biomarkers for gastric cancer.","authors":"Matilde Callegarin, Valentina Angerilli, Jessica Gasparello, Matteo Fassan","doi":"10.1080/14737159.2025.2573461","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Gastric cancer (GC) is the fifth most common malignancy worldwide and it is associated with a poor prognosis, with most cases diagnosed at an advanced stage. In the advanced/metastatic setting, targeted treatments are assuming an increasingly central role. To assess the eligibility to these agents it is essential the evaluation of predictive biomarkers.</p><p><strong>Areas covered: </strong>This review will provide an analysis of both established and novel predictive biomarkers for GC. Biomarkers currently adopted in clinical practice include HER2 overexpression/ERBB2 amplification, PD-L1 expression and MMR/MSI status, with CLDN18.2 expression as a recent addition. Other predictive biomarkers currently under evaluation include FGFR2b expression, EBV status, MET overexpression/MET amplification, EGFR amplification and VEGF/VEGFR status.</p><p><strong>Expert opinion: </strong>The increasing number of targeted therapies is revolutionizing the treatment landscape of advanced GC, but some critical challenges remain to be addressed. These include issues related to the amount of available tissue samples, spatial and temporal heterogeneity of biomarkers expression and interobserver variability, as well as issues in the identification of the most appropriate therapeutic strategy in the presence of overlapping biomarkers positivity. To address these problems, interdisciplinary collaboration between pathologists and clinicians is essential.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"1-21"},"PeriodicalIF":3.6000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737159.2025.2573461","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Gastric cancer (GC) is the fifth most common malignancy worldwide and it is associated with a poor prognosis, with most cases diagnosed at an advanced stage. In the advanced/metastatic setting, targeted treatments are assuming an increasingly central role. To assess the eligibility to these agents it is essential the evaluation of predictive biomarkers.
Areas covered: This review will provide an analysis of both established and novel predictive biomarkers for GC. Biomarkers currently adopted in clinical practice include HER2 overexpression/ERBB2 amplification, PD-L1 expression and MMR/MSI status, with CLDN18.2 expression as a recent addition. Other predictive biomarkers currently under evaluation include FGFR2b expression, EBV status, MET overexpression/MET amplification, EGFR amplification and VEGF/VEGFR status.
Expert opinion: The increasing number of targeted therapies is revolutionizing the treatment landscape of advanced GC, but some critical challenges remain to be addressed. These include issues related to the amount of available tissue samples, spatial and temporal heterogeneity of biomarkers expression and interobserver variability, as well as issues in the identification of the most appropriate therapeutic strategy in the presence of overlapping biomarkers positivity. To address these problems, interdisciplinary collaboration between pathologists and clinicians is essential.
期刊介绍：
Expert Review of Molecular Diagnostics (ISSN 1473-7159) publishes expert reviews of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking diagnostic and prognostic technologies to be used in the clinical diagnostic setting.
Each issue of Expert Review of Molecular Diagnostics contains leading reviews on current and emerging topics relating to molecular diagnostics, subject to a rigorous peer review process; editorials discussing contentious issues in the field; diagnostic profiles featuring independent, expert evaluations of diagnostic tests; meeting reports of recent molecular diagnostics conferences and key paper evaluations featuring assessments of significant, recently published articles from specialists in molecular diagnostic therapy.
Expert Review of Molecular Diagnostics provides the forum for reporting the critical advances being made in this ever-expanding field, as well as the major challenges ahead in their clinical implementation. The journal delivers this information in concise, at-a-glance article formats: invaluable to a time-constrained community.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
